vs
CORVEL CORP（CRVL）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
CORVEL CORP的季度营收约是REPLIGEN CORP的1.2倍（$235.6M vs $197.9M），CORVEL CORP净利率更高（10.3% vs 6.7%，领先3.5%），REPLIGEN CORP同比增速更快（13.6% vs 3.4%），CORVEL CORP自由现金流更多（$35.2M vs $17.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 6.6%）
Corvel Corp是一家总部位于美国的综合解决方案供应商，核心业务涵盖工伤赔偿、医疗管理与风险缓释，服务客户包括保险公司、自保雇主及公共部门机构，可帮助客户控制医疗成本、提升护理效果、优化行政运营流程。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
CRVL vs RGEN — 直观对比
营收规模更大
CRVL
是对方的1.2倍
$197.9M
营收增速更快
RGEN
高出10.3%
3.4%
净利率更高
CRVL
高出3.5%
6.7%
自由现金流更多
CRVL
多$17.6M
$17.6M
两年增速更快
RGEN
近两年复合增速
6.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $235.6M | $197.9M |
| 净利润 | $24.2M | $13.3M |
| 毛利率 | 23.3% | 52.5% |
| 营业利润率 | 13.7% | 9.0% |
| 净利率 | 10.3% | 6.7% |
| 营收同比 | 3.4% | 13.6% |
| 净利润同比 | 1.7% | 143.9% |
| 每股收益（稀释后） | $0.47 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRVLRGEN
| Q4 25 | $235.6M | $197.9M | ||
| Q3 25 | $239.6M | $188.8M | ||
| Q2 25 | $234.7M | $182.4M | ||
| Q1 25 | $231.5M | $169.2M | ||
| Q4 24 | $228.0M | $174.1M | ||
| Q3 24 | $224.4M | $154.9M | ||
| Q2 24 | $211.7M | $154.1M | ||
| Q1 24 | $207.2M | $151.3M |
净利润CRVLRGEN
| Q4 25 | $24.2M | $13.3M | ||
| Q3 25 | $27.9M | $14.9M | ||
| Q2 25 | $27.2M | $14.9M | ||
| Q1 25 | $26.4M | $5.8M | ||
| Q4 24 | $23.8M | $-30.3M | ||
| Q3 24 | $23.4M | $-654.0K | ||
| Q2 24 | $21.6M | $3.3M | ||
| Q1 24 | $19.5M | $2.1M |
毛利率CRVLRGEN
| Q4 25 | 23.3% | 52.5% | ||
| Q3 25 | 24.3% | 53.2% | ||
| Q2 25 | 24.2% | 50.0% | ||
| Q1 25 | 25.0% | 53.6% | ||
| Q4 24 | 23.2% | 26.1% | ||
| Q3 24 | 22.6% | 50.0% | ||
| Q2 24 | 22.7% | 49.8% | ||
| Q1 24 | 20.9% | 49.5% |
营业利润率CRVLRGEN
| Q4 25 | 13.7% | 9.0% | ||
| Q3 25 | 15.0% | 8.9% | ||
| Q2 25 | 15.0% | 7.6% | ||
| Q1 25 | 14.4% | 3.9% | ||
| Q4 24 | 13.5% | -17.7% | ||
| Q3 24 | 12.8% | -5.1% | ||
| Q2 24 | 13.2% | 1.0% | ||
| Q1 24 | 10.9% | 1.3% |
净利率CRVLRGEN
| Q4 25 | 10.3% | 6.7% | ||
| Q3 25 | 11.6% | 7.9% | ||
| Q2 25 | 11.6% | 8.2% | ||
| Q1 25 | 11.4% | 3.4% | ||
| Q4 24 | 10.4% | -17.4% | ||
| Q3 24 | 10.4% | -0.4% | ||
| Q2 24 | 10.2% | 2.2% | ||
| Q1 24 | 9.4% | 1.4% |
每股收益（稀释后）CRVLRGEN
| Q4 25 | $0.47 | $0.24 | ||
| Q3 25 | $0.54 | $0.26 | ||
| Q2 25 | $0.52 | $0.26 | ||
| Q1 25 | $-1.23 | $0.10 | ||
| Q4 24 | $0.46 | $-0.55 | ||
| Q3 24 | $1.35 | $-0.01 | ||
| Q2 24 | $1.25 | $0.06 | ||
| Q1 24 | $1.12 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $230.0M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $375.7M | $2.1B |
| 总资产 | $644.8M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资CRVLRGEN
| Q4 25 | $230.0M | $767.6M | ||
| Q3 25 | $207.5M | $748.7M | ||
| Q2 25 | $202.0M | $708.9M | ||
| Q1 25 | $170.6M | $697.2M | ||
| Q4 24 | $162.9M | $757.4M | ||
| Q3 24 | $138.3M | $784.0M | ||
| Q2 24 | $131.9M | $809.1M | ||
| Q1 24 | $105.6M | $780.6M |
总债务CRVLRGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CRVLRGEN
| Q4 25 | $375.7M | $2.1B | ||
| Q3 25 | $362.8M | $2.1B | ||
| Q2 25 | $342.5M | $2.1B | ||
| Q1 25 | $322.0M | $2.0B | ||
| Q4 24 | $300.9M | $2.0B | ||
| Q3 24 | $282.8M | $2.0B | ||
| Q2 24 | $263.9M | $2.0B | ||
| Q1 24 | $247.6M | $2.0B |
总资产CRVLRGEN
| Q4 25 | $644.8M | $2.9B | ||
| Q3 25 | $611.7M | $2.9B | ||
| Q2 25 | $597.4M | $2.9B | ||
| Q1 25 | $546.0M | $2.9B | ||
| Q4 24 | $538.8M | $2.8B | ||
| Q3 24 | $518.6M | $2.8B | ||
| Q2 24 | $486.2M | $2.9B | ||
| Q1 24 | $454.7M | $2.8B |
负债/权益比CRVLRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $46.1M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $35.2M | $17.6M |
| 自由现金流率自由现金流/营收 | 14.9% | 8.9% |
| 资本支出强度资本支出/营收 | 4.7% | 4.1% |
| 现金转化率经营现金流/净利润 | 1.91× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $104.3M | $93.9M |
8季度趋势，按日历期对齐
经营现金流CRVLRGEN
| Q4 25 | $46.1M | $25.7M | ||
| Q3 25 | $25.0M | $48.1M | ||
| Q2 25 | $55.0M | $28.6M | ||
| Q1 25 | $22.9M | $15.0M | ||
| Q4 24 | $41.6M | $39.2M | ||
| Q3 24 | $22.3M | $49.3M | ||
| Q2 24 | $40.4M | $42.2M | ||
| Q1 24 | $15.2M | $44.7M |
自由现金流CRVLRGEN
| Q4 25 | $35.2M | $17.6M | ||
| Q3 25 | $15.3M | $43.4M | ||
| Q2 25 | $39.5M | $21.5M | ||
| Q1 25 | $14.3M | $11.4M | ||
| Q4 24 | $32.1M | $33.6M | ||
| Q3 24 | $12.4M | $42.3M | ||
| Q2 24 | $32.8M | $37.4M | ||
| Q1 24 | $5.2M | $36.4M |
自由现金流率CRVLRGEN
| Q4 25 | 14.9% | 8.9% | ||
| Q3 25 | 6.4% | 23.0% | ||
| Q2 25 | 16.8% | 11.8% | ||
| Q1 25 | 6.2% | 6.8% | ||
| Q4 24 | 14.1% | 19.3% | ||
| Q3 24 | 5.5% | 27.3% | ||
| Q2 24 | 15.5% | 24.3% | ||
| Q1 24 | 2.5% | 24.0% |
资本支出强度CRVLRGEN
| Q4 25 | 4.7% | 4.1% | ||
| Q3 25 | 4.1% | 2.5% | ||
| Q2 25 | 6.6% | 3.9% | ||
| Q1 25 | 3.7% | 2.1% | ||
| Q4 24 | 4.2% | 3.2% | ||
| Q3 24 | 4.4% | 4.5% | ||
| Q2 24 | 3.6% | 3.1% | ||
| Q1 24 | 4.8% | 5.5% |
现金转化率CRVLRGEN
| Q4 25 | 1.91× | 1.93× | ||
| Q3 25 | 0.90× | 3.23× | ||
| Q2 25 | 2.02× | 1.92× | ||
| Q1 25 | 0.87× | 2.57× | ||
| Q4 24 | 1.75× | — | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | 1.87× | 12.70× | ||
| Q1 24 | 0.78× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRVL
| Patient Management Services | $146.1M | 62% |
| Network Solutions Services | $89.6M | 38% |
RGEN
暂无分部数据
